LexaGene’s MiQLab ™ System Selected to Be One of the Show’s Top Stars at Industry’s 47th Annual … | Nation / World
BEVERLY, Mass., October 27, 2021 (GLOBE NEWSWIRE) – LexaGene Holdings, Inc., ( OTCQB: LXXGF; TSX-V: LXG ) (“LexaGene” or the “Company”), a molecular diagnostics company that has marketed an instrument for automated multiplex PCR testing for veterinary diagnostics, today announced that it has been selected as a flagship company at the show Petcare Innovation Summit to be held in Boston, MA, in early December.
Dr. Jack Regan, CEO and Founder of LexaGene, said: “It is an honor that LexaGene has been selected from among the many applicants. I am delighted that the selection committee recognized how innovative and revolutionary the MiQLab system is for the veterinary industry. The MiQLab enables evidence-based decision making in the hospital setting, so antimicrobials are prescribed only when needed and are selected appropriately. I am delighted that LexaGene is leading the way in promoting a new wave of diagnostic testing for the veterinary market. This commitment gives the Company the opportunity to speak directly to industry leaders as well as investors focused on financing innovative life science companies.
Start-ups and emerging pet care brands are invited to the Petcare Innovation Summit, where introductions can accelerate growth, strengthen the investment pipeline, and expose brands to executives looking for game changers within. industry.
According to the organizers of the Summit:
- over US $ 110 billion will be spent in the pet industry in 2021
- over 65% of all American families own a pet
- during COVID-19 pandemic, nearly one in three Americans adopted a pet
- millennials now account for the largest share of pet owners in the United States
Dr Regan continued, “The veterinary industry is booming and we don’t see any signs of slowing down. Most vets are overwhelmed by the flood of new pets from pandemic-fueled adoptions and LexaGene’s MiQLab System offers these vets a much more efficient way to diagnose and treat animals, which will minimize the number. return visits due to unresolved infections.
The 47th Annual Petcare Innovation Summit will be held in Boston, MA, December 7-8 at the Hilton Back Bay hotel. To register for the conference, visit their website.
The LexaGene MiQLab System is designed for clinical use and detects common bacterial infections and antimicrobial resistance factors, returning results in ~ 2 hours versus several days for laboratory results.
On behalf of the board of directors
Dr Jack Regan
Managing Director & Chairman
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostic company that develops molecular diagnostic systems for the detection of pathogens and genetic testing for other molecular markers for rapid on-site testing in veterinary diagnostics, food safety and for use on open access markets such as clinical research, agricultural testing and biodefense. End users simply need to take a sample, load it onto the instrument with a sample preparation cartridge, enter the sample ID and press “Go”. The MiQLab ™ System offers excellent sensitivity, specificity and detection range and can return results in approximately two hours. The unique open access feature is designed for custom testing so end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including availability of funds, results of fundraising efforts, success of technology development efforts, cost of purchasing critical parts, instrument performance, market acceptance of the technology , regulatory acceptance and licensing issues – which could cause actual results to differ materially from the Company’s expectations, as disclosed in Company documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
Corporate and media contact: Gail Winslow Director of Marketing firstname.lastname@example.org 978.482.6237 email@example.com 800.215.1824 Investors: Sharon Choe Vice-president LaVoieHealthScience firstname.lastname@example.org (857) 241-7393
Copyright 2021 GlobeNewswire, Inc.